Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.06 AUD
Change Today 0.00 / 0.00%
Volume 2.2M
As of 12:20 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

151 Macquarie Street

Level 7

Sydney, NSW 2000


Phone: 61 2 9276 1224

Fax: 61 2 8569 1880

Prima BioMed Ltd engages in the development of personalized bio-therapeutic products for cancer. Products The company’s major product candidate in development is CVac, an autologous dendritic cell based product in clinical trials for late stage ovarian cancer patients in complete remission. CVac Clinical Development for the Treatment of Ovarian Cancer Patients in Remission The company’s major program is the treatment of epithelial ovarian cancer patients who are in complete remission. It is targeting patients in second remission. The company has obtained orphan indication designation in both the United States and Europe. In October and November 2012, the company reported positive interim data from its ongoing phase 2 trial of CVac as maintenance treatment of epithelial ovarian cancer (the CAN-003 study). In September 2013, the company announced top-line results of its CAN-003 trial. Intellectual Property CVac is protected in the major markets and various other countries by two patent families licensed from the Burnet Institute in Melbourne, Australia, including composition of matter patents on mucin-mannan conjugates and method of composition patents of producing dendritic cells treated with mannosylated fusion protein. CVac is a registered trademark in Australia, the United States, Europe, New Zealand, China, and the UAE. Regulatory Authorities The company, and any manufacturers of its products, is required to comply with applicable U.S. Food and Drug Administration manufacturing requirements contained in the U.S. Food and Drug Administration’s GMP regulations. Significant Events In May 2015, Prima BioMed Ltd. announced a collaboration with NEC Corporation and Yamaguchi University for Immutep's IMP321 in combination with a peptide vaccine developed by NEC and Yamaguchi University.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.06 AUD 0.00

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 77.5x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 73.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at